How did researchers determine that Beclin-1 was not a significant prognostic marker in untreated tumors?

• A. There was a significant difference in MCT-specific survival
• B. There was no significant difference in MCT-specific survival or DFI when all primary dermal and subcutaneous MCTs not treated with adjunctive therapy were evaluated both together and separately
• C. Beclin-1 predicted disease-free interval
• D. The study assessed only dermal tumors

Answer: (B)

Beclin-1’s prognostic value is tested by seeing whether its expression level correlates with outcomes like survival and disease-free interval in a well-defined, untreated tumor group so treatment effects don’t confuse the result. In this study, researchers looked at all primary dermal and subcutaneous mast cell tumors that did not receive adjunctive therapy, and analyzed outcomes both when all tumors were together and when dermal and subcutaneous tumors were analyzed separately. They found no significant differences in mast cell tumor–specific survival or in disease-free interval between Beclin-1 groups in either analysis. This lack of association indicates Beclin-1 does not provide prognostic information in untreated tumors under these conditions. If there had a true prognostic effect, one would expect to see a meaningful difference in survival or DFI linked to Beclin-1 status in either the combined or stratified analyses.